MARPAI REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Rhea-AI Summary

Marpai (OTCQX: MRAI) reported Q3 2024 financial results showing mixed performance in its turnaround efforts. Net revenues were $7.0 million, down 20% year-over-year. Operating expenses decreased by 36% to $10.1 million, while operating loss improved by 57% to $3.1 million. Net loss decreased by 51% to $3.6 million, with basic and diluted earnings per share at ($0.30), an improvement of $0.68 per share year-over-year. The company, which operates as a Third-Party Administrator in the $22 billion TPA market, plans to announce new developments in Q4 2024.

Positive

• Operating expenses reduced by 36% year-over-year to $10.1 million
• Operating loss improved by 57% to $3.1 million
• Net loss decreased by 51% to $3.6 million
• Earnings per share improved by $0.68 year-over-year

Negative

• Net revenues declined 20% year-over-year to $7.0 million
• Company still operating at a loss of $3.6 million
• Negative earnings per share of ($0.30)

Turnaround continues to gain traction

TAMPA, Fla., Nov. 11, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, announced financial results for the third quarter of 2024. The Company expects to hold a webcast to discuss the results on November 12, 2024.

Q3 2024 Financial Highlights:

• Net revenues were approximately $7.0 million for the three months ended September 30, 2024, down $1.7 million, or 20% lower year over year, compared to the three months ended September 30, 2023.
• Operating expenses were $10.1 million for the three months ended September 30, 2024, down $5.7 million, or 36% lower year over year compared to the three months ended September 30, 2023.
• Operating loss was $3.1 million for the three months ended September 30, 2024, lower by $4.0 million, or 57% lower year over year compared to the three months ended September 30, 2023.
• Net loss was $3.6 million for the three months ended September 30, 2024, lower by $3.7 million, or 51% lower year over year compared to the three months ended September 30, 2023.
• Basic and diluted earnings per share were ($0.30) for the three months ended September 30, 2024, up $0.68 per share year over year compared to the three months ended September 30, 2023.

"As you can see from our highlights, we continue to make strong progress with our turnaround efforts. Our goal remains profitability and positive cash flow," said Damien Lamendola, Chief Executive Officer of Marpai. "We have some exciting developments that we will be announcing in the fourth quarter."

Webcast and Conference Call Information

Marpai expects to host a conference call and webcast on Tuesday,  November 12, 2024, at 8:30 a.m. ET to review the Company's operational and financial highlights for its third quarter ended September 30, 2024.

Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/Jd298rR8DBe

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses that it continues to make strong progress with its turnaround efforts, that its goal remains profitability and positive cash flow and that it expects to have some exciting developments that it will be announcing in the fourth quarter. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

MARPAI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(in thousands, except share and per share data)
(Unaudited)
		September 30, 2024		December 31, 2023
ASSETS:
Current assets:
Cash and cash equivalents		$                          830		$                              1,147
Restricted cash		10,978		12,345
Accounts receivable, net of allowance for credit losses of $0 and $25		1,228		1,124
Unbilled receivable		579		768
Due from buyer for sale of business unit		500		800
Prepaid expenses and other current assets		771		901
Total current assets		14,886		17,085
Property and equipment, net		514		611
Capitalized software, net		752		2,127
Operating lease right-of-use assets		2,192		2,373
Goodwill		—		3,018
Intangible assets, net		—		5,177
Security deposits		1,248		1,267
Other long-term asset		15		22
Total assets		$                     19,607		$                            31,680
LIABILITIES AND STOCKHOLDERS'  (DEFICIT) EQUITY
Current liabilities:
Accounts payable		$                       3,764		$                              4,649
Accrued expenses		2,957		2,816
Accrued fiduciary obligations		7,969		11,573
Deferred revenue		1,390		661
Current portion of operating lease liabilities		559		512
Current portion of convertible debenture, net		1,540		—
Other short-term liabilities		—		632
Total current liabilities		18,179		20,843
Other long-term liabilities		20,467		19,401
Convertible debenture, net of current portion		4,072		—
Operating lease liabilities, net of current portion		3,257		3,684
Deferred tax liabilities		1,190		1,190
Total liabilities		47,165		45,118
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' (DEFICIT) EQUITY
Common stock, $0.0001 par value, 227,791,050 shares authorized; 13,747,982 shares and 7,960,938 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		1		1
Additional paid-in capital		70,119		63,307
Accumulated deficit		(97,678)		(76,746)
Total stockholders' (deficit) equity		(27,558)		(13,438)
Total liabilities and stockholders' (deficit) equity		$                     19,607		$                            31,680

 

MARPAI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
		Three Months Ended
		September 30, 2024		September 30, 2023
Revenue		$                       7,008		$                              8,729
Costs and expenses
Cost of revenue (exclusive of depreciation and amortization    shown separately below)		5,033		5,691
General and administrative		2,813		4,986
Sales and marketing		345		1,842
Information technology		1,273		1,269
Research and development		7		267
Depreciation and amortization		213		927
Loss on disposal of assets		—		7
Loss on sale of business unit		73		—
Facilities		311		769
Total costs and expenses		10,068		15,758
Operating loss		(3,060)		(7,029)
Other income (expenses)
Other income		119		130
Interest expense, net		(620)		(383)
Foreign exchange (loss) gain		1		(14)
Loss before provision for income taxes		(3,560)		(7,296)
Income tax expense		—		—
Net loss		$                     (3,560)		$                            (7,296)
Net loss per share, basic & fully diluted		$                       (0.30)		$                              (0.98)
Weighted average common shares outstanding, basic and    diluted		12,043,931		7,479,401

 

MARPAI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
		Nine Months Ended
		September 30, 2024		September 30, 2023
Revenue		$                     21,582		$                            28,448
Costs and expenses
Cost of revenue (exclusive of depreciation and amortization    shown separately below)		15,078		18,530
General and administrative		9,954		15,938
Sales and marketing		1,383		5,494
Information technology		3,608		4,775
Research and development		22		1,291
Depreciation and amortization		2,078		2,974
Impairment of goodwill and intangible assets		7,588		—
Loss on disposal of assets		—		350
Loss on sale of business unit		73		—
Facilities		1,197		1,918
Total costs and expenses		40,981		51,270
Operating loss		(19,399)		(22,822)
Other income (expenses)
Other income		360		231
Interest expense, net		(1,890)		(1,102)
Foreign exchange (loss) gain		(3)		(32)
Loss before provision for income taxes		(20,932)		(23,725)
Income tax expense		—		—
Net loss		$                   (20,932)		$                          (23,725)
Net loss per share, basic & fully diluted		$                       (1.96)		$                              (3.62)
Weighted average common shares outstanding, basic and    diluted		10,697,008		6,552,575

 

MARPAI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, except share and per share data)
(Unaudited)
		Nine Months Ended
		September 30, 2024		30-Sep-23
Cash flows from operating activities:
Net loss		$                   (20,932)		$                          (23,725)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,078		2,974
Loss on disposal of assets		—		350
Loss on sale of receivables		306		—
Share-based compensation		2,786		1,837
Loss on sale of business unit		73		—
Common Stock issued to vendors in exchange for services		—		79
Amortization of right-of-use asset		181		1,289
Gain on termination of lease		—		33
Impairment of goodwill and intangible assets		7,588		—
Non-cash interest		975		1,204
Amortization of debt discount and debt issuance costs		128		—
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivable		85		639
Prepaid expense and other assets		136		216
Due from buyer for sale of business unit		227		—
Security deposit		19		(16)
Accounts payable		(885)		336
Accrued expenses		141		(693)
Accrued fiduciary obligations		(3,604)		853
Operating lease liabilities		(380)		(1,670)
Due To related party		—		(3)
Other liabilities		827		973
Net cash used in operating activities		(10,251)		(15,324)
Cash flows from investing activities:
Disposal of property and equipment		—		27
Net cash provided by (used in) investing activities		—		27
Cash flows from financing activities:
Proceeds from issuance of common stock in a public offering, net		—		6,432
Proceeds from sale of future cash receipts on accounts receivable		1,509		—
Proceeds from issuance of convertible debentures		5,978		—
Payments of convertible debenture issuance costs		(499)		—
Payments to buyer of receivables		(1,816)		—
Payments to seller for acquisition		(631)		—
Proceeds from issuance of common stock in a private offering, net		4,026		—
Net cash provided by financing activities		8,567		6,432
Net decrease in cash, cash equivalents and restricted cash		(1,684)		(8,865)
Cash, cash equivalents and restricted cash at beginning of period		13,492		23,117
Cash, cash equivalents and restricted cash at end of period		$                     11,808		$                            14,252
Reconciliation of cash, cash equivalents, and restricted cash reported in    the condensed consolidated balance sheet
Cash and cash equivalents		$                          830		$                              3,018
Restricted cash		10,978		11,234
Total cash, cash equivalents and restricted cash shown in the condensed    consolidated statement of cash flows		$                     11,808		$                            14,252
Supplemental disclosure of cash flow information
Cash paid for interest		$                       1,508		$                                   —
Supplemental disclosure of non-cash activity
Measurement period adjustment to Goodwill		$                            —		$                                198

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-third-quarter-2024-financial-results-302301678.html

SOURCE Marpai

FAQ

What were Marpai's (MRAI) Q3 2024 revenue results?

Marpai reported Q3 2024 net revenues of $7.0 million, representing a 20% decrease compared to Q3 2023.

How much did Marpai (MRAI) reduce its operating loss in Q3 2024?

Marpai reduced its operating loss by 57% year-over-year to $3.1 million in Q3 2024.

What was Marpai's (MRAI) earnings per share for Q3 2024?

Marpai reported basic and diluted earnings per share of ($0.30) for Q3 2024, an improvement of $0.68 per share compared to Q3 2023.